Finasteride
Also known as: Propecia · Proscar · 5-Alpha-Reductase Inhibitor
Finasteride reduces scalp DHT and is the most evidence-based oral therapy for androgenetic alopecia. Provider-reviewed candidacy, side-effect counseling, and longitudinal monitoring are standard.
Inhibits type II 5-alpha-reductase, reducing conversion of testosterone to dihydrotestosterone (DHT) and slowing follicular miniaturization in androgenetic alopecia.
What you need to know
Finasteride lowers scalp DHT by roughly 60–70% at standard dosing and is the most studied oral pathway for androgenetic alopecia. Onset of measurable response is typically 3–6 months. Provider-reviewed evaluation covers candidacy, side-effect counseling (libido, sexual function, mood — incidence is low but non-zero), and monitoring. Finasteride is often combined with topical minoxidil for additive effect.
How this entity relates
Every entity in the oMeds knowledge graph cross-links to the conditions, biomarkers, medications, and educational surfaces it touches.
Bring this entity into your optimization pathway
Every condition, symptom, biomarker, and medication on oMeds is reviewed by a licensed provider and recalibrated against the standardized biomarker panel.